News

30. 06. 2020 Eveliqure secures further private investment to support development of its combined Shigella and ETEC vaccine candidate | Download 

02. 06. 2020 Eveliqure announces regulatory approval to commence first clinical studies with its combined Shigella and ETEC vaccine | Download 

05. 11. 2019 Eveliqure's effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries is supported by the Wellcome Trust | Download 

25. 10. 2019 The Austrian Research Promotion Agency (FFG) featured Eveliqure and the SHIGETECVAX Horizon2020 consortium project in its 'Success Story' series | Read 

10.09.2019 Eveliqure's diarrhoea vaccine to advance towards clinical trials supported by significant Horizon2020 award. | Download

Headquarters

Eveliqure Biotechnologies GmbH

Campus Vienna Biocenter


Karl-Farkas-Gasse 22

A-1030 Vienna

Austria

  • White Facebook Icon
  • White LinkedIn Icon

© 2019 Eveliqure Biotechnologies GmbH